Edwards Lifesciences Corporation(EW) 종목 분석 — 적정가치·리스크·해자 평가

Edwards Lifesciences Corporation (EW) stock price is $81.53 as of the latest market close, traded on the NYSE exchange.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.

Edwards Lifesciences Corporation has a market capitalization of $47.35B, classifying it as a large-cap stock in the Healthcare sector.

Edwards Lifesciences Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. It trades on the NYSE under the ticker symbol EW.

Based on our valuation model, Edwards Lifesciences Corporation trades 7.0% below our fair value estimate — potentially undervalued.

• FairValueLabs Fair Value: $87.71
• Current Price: $81.53
• Valuation Zone: Watch Zone

Based on 27 Wall Street analysts, the consensus price target for Edwards Lifesciences Corporation is $96.33, implying upside of 18.2% from the current price.

• Analyst High Target: $110.00
• Analyst Low Target: $84.00

Note: Analyst targets are shown for reference and are not used in our valuation model.

Here are the analyst consensus growth estimates for Edwards Lifesciences Corporation:

• Revenue growth (current year est.): 10.0%
• EPS growth (current year est.): 16.0%
• Revenue growth (next year est.): 9.9%
• EPS growth (next year est.): 11.8%

The price-to-earnings ratio measures how much investors pay per dollar of earnings:

• Trailing P/E (last 12 months): 45.0x
• Forward P/E (next 12 months est.): 24.6x
• FairValueLabs Fair P/E: 38.3x

Edwards Lifesciences Corporation has a beta of 0.94, meaning it is roughly in line with overall market volatility. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.

Edwards Lifesciences Corporation's balance sheet shows:

• Total Cash: $4.23B
• Total Debt: $705.4M
• Net Cash Position: $3.52B

A positive net cash position means the company holds more cash than debt, reducing financial risk.

Edwards Lifesciences Corporation generated $1.17B in trailing twelve-month free cash flow (from $1.60B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.

Edwards Lifesciences Corporation does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.

Edwards Lifesciences Corporation's Altman Z-Score is 11.10, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.

Edwards Lifesciences Corporation scores 3.1/5 stars (Narrow moat) in our moat analysis:

• ROIC Stability: 4/5
• Gross Margin Trend: 2/5
• Switching Costs: 3/5

A score above 3.5 suggests meaningful pricing power and a defensible market position.

Edwards Lifesciences Corporation's return on equity is 10.3%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.

EW shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:

1. Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
2. Search for ticker symbol EW
3. Place a market or limit order for your desired number of shares

This is not investment advice. Always do your own research before buying any stock.

FairValueLabs classifies Edwards Lifesciences Corporation as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.

The current CEO of Edwards Lifesciences Corporation is Mr. Bernard J. Zovighian.

Earnings per share measures the company's profit allocated to each outstanding share:

• Trailing EPS (last 12 months): $1.81
• Forward EPS (next 12 months est.): $3.32
• Analyst consensus EPS (this year): $2.97
• Analyst consensus EPS (next year): $3.32